- Home
- RGNX
RGNX
REGENXBIO Inc.
as 01-21-2025 4:00pm EST
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 372.1M | IPO Year: | 2015 |
| Target Price: | $35.55 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.56 - $28.80 | Next Earning Date: | 02-25-2025 |
| Revenue: | $84,327,000 | Revenue Growth: | -15.14% |
| Revenue Growth (this year): | 2.92% | Revenue Growth (next year): | 256.82% |
Latest REGENXBIO Inc. News
RGNX Breaking Stock News: Dive into RGNX Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
6 days ago
Regenxbio and Nippon Shinyaku forge $810m gene therapy deal
BioPharma Dive
8 days ago
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku
MT Newswires
8 days ago
REGENXBIO, Nippon Shinyaku Partner to Advance Drug Candidates for Certain Genetic Disorders in US, Asia
PR Newswire
8 days ago
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
PR Newswire
9 days ago
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
TipRanks
14 days ago
Regenxbio price target lowered to $22 from $25 at BofA
MT Newswires
15 days ago
BofA Securities Adjusts Price Target on REGENXBIO to $22 From $25, Maintains Buy Rating
MT Newswires
15 days ago
RBC Lowers Price Target on REGENXBIO to $30 From $35, Keeps Outperform, Speculative Risk
Compare RGNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGNX REGENXBIO Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.